|
|
|
|
LEADER |
01000caa a22002652 4500 |
001 |
ELV053262956 |
003 |
DE-627 |
005 |
20230624193341.0 |
007 |
cr uuu---uuuuu |
008 |
210910s2021 xx |||||o 00| ||eng c |
024 |
7 |
|
|a 10.1016/j.pcd.2020.10.002
|2 doi
|
028 |
5 |
2 |
|a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001496.pica
|
035 |
|
|
|a (DE-627)ELV053262956
|
035 |
|
|
|a (ELSEVIER)S1751-9918(20)30287-4
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
082 |
0 |
4 |
|a 630
|q VZ
|
082 |
0 |
4 |
|a 640
|q VZ
|
082 |
0 |
4 |
|a 590
|q VZ
|
082 |
0 |
4 |
|a 610
|q VZ
|
082 |
0 |
4 |
|a 600
|q VZ
|
084 |
|
|
|a 50.70
|2 bkl
|
100 |
1 |
|
|a Tumminia, Andrea
|e verfasserin
|4 aut
|
245 |
1 |
0 |
|a Efficacy, renal safety and tolerability of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in elderly patients with type 2 diabetes: A real-world experience
|
264 |
|
1 |
|c 2021
|
300 |
|
|
|a 6
|
336 |
|
|
|a nicht spezifiziert
|b zzz
|2 rdacontent
|
337 |
|
|
|a nicht spezifiziert
|b z
|2 rdamedia
|
338 |
|
|
|a nicht spezifiziert
|b zu
|2 rdacarrier
|
520 |
|
|
|a • Older patients with T2DM are often excluded from randomized controlled trials. • The insulin-independent mechanism of action makes SGLT2i suitable in the elderly. • Our study focused on SGLT2i-treated older patients with T2DM, stratified by age (65–69 and ≥70 years). • HbA1c reduction, eGFR variation and tolerability were similar across age groups. • Among elderly T2DM individuals, SGLT2i are effective, safe and fairly well tolerated.
|
650 |
|
7 |
|a Type 2 diabetes
|2 Elsevier
|
650 |
|
7 |
|a Elderly
|2 Elsevier
|
650 |
|
7 |
|a Sodium-glucose cotransporter 2 inhibitors
|2 Elsevier
|
650 |
|
7 |
|a Real-world evidence
|2 Elsevier
|
700 |
1 |
|
|a Graziano, Marco
|4 oth
|
700 |
1 |
|
|a Vinciguerra, Federica
|4 oth
|
700 |
1 |
|
|a Lomonaco, Andrea
|4 oth
|
700 |
1 |
|
|a Frittita, Lucia
|4 oth
|
773 |
0 |
8 |
|i Enthalten in
|n Elsevier
|a David, Lauren A. ELSEVIER
|t A pilot randomized controlled trial examining the feasibility, acceptability, and efficacy of Adapted Motivational Interviewing for post-operative bariatric surgery patients
|d 2016
|g Amsterdam [u.a.]
|w (DE-627)ELV024210129
|
773 |
1 |
8 |
|g volume:15
|g year:2021
|g number:2
|g pages:283-288
|g extent:6
|
856 |
4 |
0 |
|u https://doi.org/10.1016/j.pcd.2020.10.002
|3 Volltext
|
912 |
|
|
|a GBV_USEFLAG_U
|
912 |
|
|
|a GBV_ELV
|
912 |
|
|
|a SYSFLAG_U
|
912 |
|
|
|a GBV_ILN_24
|
912 |
|
|
|a GBV_ILN_40
|
912 |
|
|
|a GBV_ILN_60
|
912 |
|
|
|a GBV_ILN_72
|
912 |
|
|
|a GBV_ILN_227
|
912 |
|
|
|a GBV_ILN_350
|
936 |
b |
k |
|a 50.70
|j Energie: Allgemeines
|q VZ
|
951 |
|
|
|a AR
|
952 |
|
|
|d 15
|j 2021
|e 2
|h 283-288
|g 6
|